Cullinan Therapeutics Presents Preclinical Data for CLN-978
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) will present new preclinical data for CLN-978 at the American College of Rheumatology (ACR) Convergence 2025.
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases.
- Presentation: Poster Session C, Poster Number 2293, October 28, 10:30 a.m.-12:30 p.m. CT
- Exhibit Hall: Booth (#1074)
CLN-978, its novel investigational CD19xCD3 bispecific T cell engager.
Cullinan Therapeutics is a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer.
Author's summary: Cullinan Therapeutics presents preclinical data for CLN-978.
More News
- Zorin OS Breaks Download Record as Windows 10 Users Seek Alternatives
- 5 members of the 2025 Yankees make list of top 50 free agents
- Renters Rights Bill becomes law - Letting Agent Today
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Three resilient UK multinationals global managers are excited about | Trustnet
- The environmental impact of the 2026 World Cup
- Sweden’s still ahead in the preparedness game — and now it means business
- Family office conflicts surge as wealthy clans grapple with two major challenges
- Battlefield 6's Battle Royale Mode Is Called REDSEC, Is Free-To-Play, And Launches Tomorrow
- Rutgers Health and University Hospital Break Ground on First Phase of Sweeping Newark Campus Redevelopment